FDA warns Legit Ketamine Suppliers website for selling unapproved, misbranded ketamine and esketamine drugs to U.S. consumers.
What happened
FDA reviewed the website www.legitketaminesuppliers.com on February 26, 2026 (Establishment Identifier 3043543369) rather than conducting an inspection. The review found the site offering ketamine marketed as "ketamine buy" and esketamine marketed as "Ketamine Nasal Spray," with claims that they treat pain and treatment-resistant depression. FDA says no approved application exists for these products and that they are sold without a prescription.
What FDA found
The website sold ketamine and esketamine products that FDA has never approved.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))Website claims that the products treat pain and depression show they are drugs intended for human use.
21 CFR 201.128The labeling does not give adequate directions for use, so the drugs are misbranded.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))The company offers prescription drugs for sale without requiring a prescription.
FD&C Act sections 503(b)(1) and 301(k) (21 U.S.C. 353(b)(1), 331(k))Unapproved drugs were introduced into interstate commerce, which the law prohibits.
FD&C Act section 301(a) (21 U.S.C. 331(a))The esketamine nasal spray is sold without the restricted distribution and monitoring program (REMS) that the approved version requires.
What FDA wants
FDA tells the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers. The company must send a written response with corrective steps and supporting documents within 15 business days of receiving the letter, citing reference number MARCS-CMS 725149.
Who should pay attention
- telehealth and online pharmacy operators
- clinics and pharmacies that handle ketamine or esketamine
- compounding pharmacies and brands selling ketamine products
This is a summary. Read the original letter on fda.gov.